125I-脱氧尿苷治疗膀胱癌的实验与临床研究

Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine

  • 摘要: 放射性核素通过电子俘获和(或)内转换衰变产生低能电子(<1 keV)的俄歇效应,掺入细胞DNA后具有显著的细胞毒性。125I-脱氧尿苷(125I-UdR)是将125I引入细胞核的有效载体,能特异性掺入S期细胞DNA。一系列研究表明,125I能更多地被肿瘤细胞吸收,而不是正常的分裂细胞,从而有效地治疗恶性病变。由于膀胱为一天然囊腔,具有独特的易灌注及观察性,膀胱灌注125I-UdR治疗膀胱癌,能高效、选择性杀伤肿瘤细胞,明显降低膀胱癌复发率,故可作为外科手术的辅助治疗手段,有希望成为一种安全、高效、不良反应小的治疗膀胱癌的新疗法。

     

    Abstract: Radionuclide can cause auger effect through disintegration low-energy electron (<1 keV) through electron entrapment and (or) internal conversion. Incorporation of Auger-electron emitters into the DNA have significant eytotoxicity, 125I-iododeoxyuridine (125I-UdR) is an efficient carrier inducting 125I to cell nucleolus, it is incorporated into DNA specificity only in S-phase cells. A series of studies show that 125I can absorb more likely to tumor cells, instead of the normal cell division, thus effectively splitting radiotherapy of malignant lesions. As bladder is a natural lumen, it has a unique easy perfusion and observational, 125I-UdR can kill effiently and selectively the cells of bladder tumour, reducing markedly the ratio of its recurrence of surgical treatment of patients with bladder cancer, so as to improve the survival rate. It can be used as a surgical adjuvant treatment method, is expected to be a safe, efficient and less adverse reaction the new therapies for bladder cancer treatment.

     

/

返回文章
返回